We need to look beyond French borders and have been actively looking for investors in the US as this is where the relevant institutional investors are
In Conversation
The TREM-1 pathway can be used to develop treatments for different indications besides septic shock, including cardiovascular diseases and chronic inflammatory conditions, which could be interesting…
We are focusing our efforts as a company to grow our dermatological portfolio and have divested other products not related to this area
Thanks to their versatility, oncolytic viruses can, therefore, be very potent. Our Invir.IO™ platform will be revolutionary for tumours that resist currently available treatments.
The acquisition of Shire products also allowed us to enter the US market, a key point in our ambition to increase our global presence
One of the biggest challenges that Vygon is facing is that the health authorities know very little about medical devices
Science is the most important asset of Ferring and my education has encouraged me to be science-driven
Today’s patients are much more involved in the health paradigm than they used to be, and this must be acknowledged by the industry
In the US, Jazz is already known for its leadership in sleep medicine. It is our expertise here that we will be bringing to France and…
Life sciences is not the company’s primary activity, but it remains a good way to keep our teams busy when the oil and gas market is…
The key success factor to answer [biotech companies'] needs is reactivity and, as a mid-size business, we have the flexibility to work with them efficiently
For any business to be successful in a foreign country, it needs to hire local talent with the knowledge and know-how to meet the needs of…
